Axsome Therapeutics (AXSM) Tops Q1 EPS by $1.03; Offers Operational Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
May 8, 2023 7:00 AM EDTAuvelity® 1Q 2023 net product sales of $15.7 million
Total 1Q 2023 net product sales of $28.6 million
Total 1Q 2023 revenue of $94.6 million, including Sunosi® ex-U.S. license agreement upfront payment
Company to host conference call today at 8:00 AM Eastern
NEW YORK, May 08, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported... More
